JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Price, Quote, News and Overview
NASDAQ:JAZZ - Nasdaq - IE00B4Q5ZN47 - Common Stock
JAZZ Quote and Key Statistics
JAZZ PHARMACEUTICALS PLC
NASDAQ:JAZZ (1/21/2025, 8:09:00 PM)
After market: 121.43 0 (0%)121.43
+0.25 (+0.21%)
JAZZ Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.6% | ||
| ROA | 3.78% | ||
| ROE | 11.1% | ||
| Debt/Equity | 1.46 |
JAZZ Performance and Technical Analysis
JAZZ Ownership and Analysts
JAZZ Latest News and Analysis
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents.
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan...
Jazz Pharmaceuticals Announces CEO Succession Plan
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has...
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, revealed by Jazz Pharmaceuticals plc (NASDAQ: JAZZ). New data on Epidiolex is being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California via nine company-sponsored posters.Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals in 2021.
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced nine company-sponsored Epidiolex® (cannabidiol) posters are being presented at the...
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intravenous use is...
About JAZZ
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The firm is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Company Info
JAZZ PHARMACEUTICALS PLC
Fifth Fl, Waterloo Exchange, Waterloo Road
DUBLIN DUBLIN D04 IE
CEO: Bruce C. Cozadd
Employees: 2800
Company Website: https://www.jazzpharma.com/
Investor Relations: http://investor.jazzpharma.com
Phone: 35316347800
JAZZ Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 72.99 | 704.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.38 | 359.88B | ||
| JNJ | JOHNSON & JOHNSON | 14.47 | 356.69B | ||
| MRK | MERCK & CO. INC. | 16.17 | 243.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.84 | 210.75B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.37 | 199.39B | ||
| PFE | PFIZER INC | 10.33 | 150.97B | ||
| SNY | SANOFI-ADR | 12.43 | 129.60B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.75 | 115.69B | ||
| ZTS | ZOETIS INC | 29.09 | 75.58B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 68.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.83 | 41.53B |